{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?questionFirstAnswered.=2019-05-22T14%3A50%3A14.483Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?questionFirstAnswered.=2019-05-22T14%3A50%3A14.483Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?questionFirstAnswered.=2019-05-22T14%3A50%3A14.483Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&questionFirstAnswered.=2019-05-22T14%3A50%3A14.483Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?questionFirstAnswered.=2019-05-22T14%3A50%3A14.483Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?questionFirstAnswered.=2019-05-22T14%3A50%3A14.483Z&AnsweringBody.=Department+of+Health+and+Social+Care&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1125505", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1125505/answer", "answerText" : {"_value" : "
The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom\u2019s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.<\/p>
The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.<\/p>
The JCVI\u2019s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.<\/p>
The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI\u2019s minutes which are attached.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1125505/answer/attachment/1", "fileName" : {"_value" : "JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf"} , "title" : "JCVI Minute 2015"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL15599"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T14:50:14.483Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pneumococcal Diseases: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"} ], "uin" : "HL15600"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }